GIFLF - Grifols, S.A.
| Previous close | 11.65 |
| Open | 11.65 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 11.65 - 11.65 |
| 52-week range | 7.90 - 21.00 |
| Volume | |
| Avg. volume | 153 |
| Market cap | 7.011B |
| Beta (5Y monthly) | 0.43 |
| PE ratio (TTM) | 35.30 |
| EPS (TTM) | 0.33 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 03 June 2021 |
| 1y target est | N/A |
GlobeNewswireGrifols Launches AlphaID™ At Home, Enabling U.S. Consumers to Self-Screen for Genetic COPD
Now available in the U.S., this free, innovative genetic health risk service lets consumers screen for their risk of alpha1-antitrypsin deficiency (alpha-1) through a small saliva sample they can collect right at home without needing to visit a healthcare professionalAlpha-1 is the most common genetic risk factor for chronic obstructive pulmonary disease (COPD), a group of respiratory diseases affecting around 16 million Americans and the fourth-leading cause of death in the U.S.1As the leader i
Motley FoolWhy Shares of Grifols Were Up Tuesday
Shares of Grifols (NASDAQ: GRFS) were up 11.1% on Tuesday afternoon, after being up as much as 13.1% earlier in the day. The pharmaceutical company, which makes plasma-derived medicines, released first-quarter earnings on Tuesday morning. The company's products range from diagnostics to detect infectious agents in blood or plasma donations, to the production of antigens used in immunoassay regents, to albumin, used to restore circulatory volume and protein loss in certain conditions.
PR NewswireGrifols 2022 Annual Report on Form 20-F filed with the SEC on April 18, 2023
Grifols, S.A. ("Grifols") (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines that has been enhancing people's health and well-being for more than 110 years, today announces the filling of its Annual Report on Form 20-F for the fiscal year ended December 31, 2022, with the United States Securities and Exchange Commission ("SEC").
ZacksAre Investors Undervaluing Grifols (GRFS) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
ZacksGrifols (GRFS) Upgraded to Strong Buy: Here's Why
Grifols (GRFS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
PR NewswireSelagine Enters into a Collaborative Agreement with Grifols for Development and Commercialization of Immunoglobulin Eye Drops for Treating Dry Eye Disease
Selagine, Inc., a spin-out company from the University of Illinois at Chicago (UIC), announced today that it has entered into a research, development and sublicense agreement with Grifols (Nasdaq: GRFS), a global leader in plasma-derived medicines, for the development and commercialization of immunoglobulin eye drops for dry eye disease.
ZacksIs Grifols (GRFS) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
ZacksIs Grifols (GRFS) a Great Value Stock Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- PR Newswire
Grifols receives FDA clearance for AlphaID™ At Home, the first free service for U.S. consumers to determine their risk for alpha-1
Grifols (MCE: GRF) (MCE:GRF.P) (NASDAQ:GRFS), a global leader in plasma-derived medicines and innovative diagnostic solutions, today announced that its AlphaID™ At Home Genetic Health Risk Service, the first-ever free direct-to-consumer program in the U.S. to screen for genetic risk of alpha1-antitrypsin deficiency (alpha-1), has been cleared by the U.S. Food and Drug Administration (FDA).
- PR Newswire
Victor Grifols Roura decides to retire as Chairperson; Grifols appoints private equity veteran Steven F. Mayer as Executive Chairperson
Grifols (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS) announced today changes to its leadership team, appointing Mr. Steven F. Mayer as Executive Chairperson while Mr. Victor Grifols Roura retired as Chairperson and was named Chairperson of Honor. Both changes are effective immediately.
GlobeNewswireGigaGen Awarded Contract by U.S. Department of Defense to Discover Synthetic Human Antibody Treatments for High-Priority Toxins and Pathogens
SOUTH SAN FRANCISCO, Calif., Sept. 15, 2022 (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for immune deficiencies, infectious diseases and checkpoint resistant cancers, and a subsidiary of Grifols, announced today it has entered into a contract with the U.S. Department of Defense’s (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) to demonstrate the utility of its first-in-class recombi
- PR Newswire
Grifols enters into agreement with Canadian Blood Services to accelerate self-sufficiency in immunoglobulins for Canada
Grifols (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS), a global leader in plasma medicines with more than 110 years contributing to improve the health and well-being of people, today announced it has signed a pioneering long-term agreement with Canadian Blood Services, Canada's national blood authority, to greatly increase the country's self-sufficiency in immunoglobulin (Ig) medicines, essential plasma-protein therapies used to treat a wide range of immunodeficiencies and other medical conditions.
- PR Newswire
Grifols Procleix Plasmodium Assay receives CE mark, a first for malaria blood screening
Grifols (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS), a global leader in the development of plasma-derived therapies and the development of innovative diagnostic solutions, today announced that its Procleix Plasmodium Assay has obtained the CE mark, the first for an automated nucleic acid test (NAT) system specifically validated for screening blood donors for malaria.